We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates
Read MoreHide Full Article
Exelixis, Inc. (EXEL - Free Report) delivered better-than-expected results for second-quarter 2020, wherein earnings and revenues beat estimates.
The company reported earnings of 21 cents per share, beating the Zacks Consensus Estimate of 12 cents. The bottom-line figure, however, declined from the year-ago quarter’s 25 cents per share due to higher R&D expenses.
Net revenues came in at $259.5 million, increasing from the $240.3 million reported in the year-ago quarter. Revenues also beat the Zacks Consensus Estimate of $233 million.
Net product revenues came in at $178.7 million, down from $193.7 reported in the year-ago quarter due to a decrease in sales volume. Net product revenues in the second quarter of 2020 were negatively impacted by the COVID-19 pandemic and an inventory built by wholesalers and end customers in the first quarter of 2020, which generally reversed in the second quarter.
Lead drug, Cabometyx, is approved in the United States for the treatment of advanced renal cell carcinoma (RCC). The drug was also approved for the treatment of patients with hepatocellular carcinoma, who have been previously treated with sorafenib, in January 2019.
Cabometyx generated $173.6 million of revenues. Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $5.1 million in net product revenues. Exelixis earned $16.3 million in royalty revenues on the basis of cabozantinib-related revenues generated by its partner, Ipsen.
In the reported quarter, research and development expenses increased to $114.9 million from the year-ago figure of $81.9 million due to a rise in clinical trial costs (COSMIC-312, COSMIC-313, CONTACT-02 and COSMIC-021). and personnel expenses. Selling, general and administrative (SG&A) expenses were $59.8 million, up from $58.8 million in the year-ago quarter.
Pipeline Update
In April 2020, Exelixis and Bristol-Myers (BMY - Free Report) announced that CheckMate -9ER, the phase III study evaluating Opdivo in combination with Cabometyx compared to Sutent in previously untreated advanced or metastatic RCC, met its primary endpoint of progression-free survival at the final analysis as well as the secondary endpoints of overall survival at a pre-specified interim analysis and objective response rate. This preliminary analysis of data showed a favorable safety profile for the combination of a 40 mg dose of cabozantinib with Opdivo.
In June and July, Exelixis announced the initiation of CONTACT-01, CONTACT-02 and CONTACT-03, three global phase III studies of cabozantinib in combination with Roche’s (RHHBY - Free Report) Tecentriq in patients with previously treated metastatic non-small cell lung cancer (NSCLC), castration-resistant prostate cancer (CRPC) and RCC, respectively.
2020 Guidance Updated
Revenues are now projected at $900-$950 million (previous guidance: $850-$900 million) while product revenues are estimated in the range of $725-$775 million for 2020.
Our Take
Exelixis’ reported better-than-expected results for the second quarter. The pipeline progress too has been encouraging and positive results of CheckMate -9ER bodes well for Cabometyx, as a tentative approval for the combination will boost demand. However, competition has stiffened from the recently-approved combination therapies. Last year, the FDA approved Merck’s (MRK - Free Report) Keytruda in combination with Inlyta for the first-line treatment of patients with advanced RCC. Given the increasing use of these therapies, we expect investors to focus on the label expansions of cabozantinib in the ongoing combination trials.
Shares of Exelixis have surged 29.4% in the year so far compared with the industry’s growth of 5.4%.
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates
Exelixis, Inc. (EXEL - Free Report) delivered better-than-expected results for second-quarter 2020, wherein earnings and revenues beat estimates.
The company reported earnings of 21 cents per share, beating the Zacks Consensus Estimate of 12 cents. The bottom-line figure, however, declined from the year-ago quarter’s 25 cents per share due to higher R&D expenses.
Net revenues came in at $259.5 million, increasing from the $240.3 million reported in the year-ago quarter. Revenues also beat the Zacks Consensus Estimate of $233 million.
Exelixis, Inc. Price, Consensus and EPS Surprise
Exelixis, Inc. price-consensus-eps-surprise-chart | Exelixis, Inc. Quote
Quarter in Detail
Net product revenues came in at $178.7 million, down from $193.7 reported in the year-ago quarter due to a decrease in sales volume. Net product revenues in the second quarter of 2020 were negatively impacted by the COVID-19 pandemic and an inventory built by wholesalers and end customers in the first quarter of 2020, which generally reversed in the second quarter.
Lead drug, Cabometyx, is approved in the United States for the treatment of advanced renal cell carcinoma (RCC). The drug was also approved for the treatment of patients with hepatocellular carcinoma, who have been previously treated with sorafenib, in January 2019.
Cabometyx generated $173.6 million of revenues. Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $5.1 million in net product revenues. Exelixis earned $16.3 million in royalty revenues on the basis of cabozantinib-related revenues generated by its partner, Ipsen.
In the reported quarter, research and development expenses increased to $114.9 million from the year-ago figure of $81.9 million due to a rise in clinical trial costs (COSMIC-312, COSMIC-313, CONTACT-02 and COSMIC-021). and personnel expenses. Selling, general and administrative (SG&A) expenses were $59.8 million, up from $58.8 million in the year-ago quarter.
Pipeline Update
In April 2020, Exelixis and Bristol-Myers (BMY - Free Report) announced that CheckMate -9ER, the phase III study evaluating Opdivo in combination with Cabometyx compared to Sutent in previously untreated advanced or metastatic RCC, met its primary endpoint of progression-free survival at the final analysis as well as the secondary endpoints of overall survival at a pre-specified interim analysis and objective response rate. This preliminary analysis of data showed a favorable safety profile for the combination of a 40 mg dose of cabozantinib with Opdivo.
In June and July, Exelixis announced the initiation of CONTACT-01, CONTACT-02 and CONTACT-03, three global phase III studies of cabozantinib in combination with Roche’s (RHHBY - Free Report) Tecentriq in patients with previously treated metastatic non-small cell lung cancer (NSCLC), castration-resistant prostate cancer (CRPC) and RCC, respectively.
2020 Guidance Updated
Revenues are now projected at $900-$950 million (previous guidance: $850-$900 million) while product revenues are estimated in the range of $725-$775 million for 2020.
Our Take
Exelixis’ reported better-than-expected results for the second quarter. The pipeline progress too has been encouraging and positive results of CheckMate -9ER bodes well for Cabometyx, as a tentative approval for the combination will boost demand. However, competition has stiffened from the recently-approved combination therapies. Last year, the FDA approved Merck’s (MRK - Free Report) Keytruda in combination with Inlyta for the first-line treatment of patients with advanced RCC. Given the increasing use of these therapies, we expect investors to focus on the label expansions of cabozantinib in the ongoing combination trials.
Shares of Exelixis have surged 29.4% in the year so far compared with the industry’s growth of 5.4%.
Zacks Rank
Exelixis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>